Taysha Gene Therapies is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. Co.'s portfolio of gene therapy candidates targets neurological indications across three therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Co.'s TSHA-101, a neurodegenerative disease product candidate, is being developed for the treatment of GM2 gangliosidosis, including Tay-Sachs disease and Sandhoff disease. Co.'s TSHA-102, a neurodevelopmental disorder product candidate, is being developed for the treatment of Rett syndrome. The TSHA stock yearly return is shown above.
The yearly return on the TSHA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TSHA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|